Core Laboratories NV (CLB)
Official siteENERGY • OIL & GAS EQUIPMENT & SERVICES • NYSE
Market Cap: $417.45M
Last updated: Nov 17, 2026 at 11:04 AM ET
Core Laboratories NV (CLB) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Core Laboratories NV reported EPS of $0.16, below the $0.17 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% below the $0.21 reported for the quarter ended Dec 31, 2025.
CLB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
CLB Earnings Call
The latest CLB earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CLB beat 22, missed 8 and matched 10. Revenue for the quarter ended Sep 30, 2026 was $132.08M, down 1.8% from $134.52M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.16 | $0.17 | $0.15 - $0.17 | -5.88% | Miss | -27.3% | 3 | 1 up, 0 down | Oct 28, 2026 | $132.08M |
| Jun 30, 2026 | $0.11 | $0.08 | $0.08 - $0.10 | +37.50% | Beat | -42.1% | 3 | 0 up, 0 down | Jul 29, 2026 | $124.61M |
| Mar 31, 2026 | $0.06 | $0.11 | $0.06 - $0.21 | -45.45% | Miss | -57.1% | 3 | 1 up, 1 down | Apr 29, 2026 | $121.80M |
| Dec 31, 2025 | $0.21 | $0.19 | $0.17 - $0.20 | +10.53% | Beat | -4.5% | 3 | 1 up, 0 down | Feb 4, 2026 | $138.25M |
| Sep 30, 2025 | $0.22 | $0.19 | $0.19 - $0.20 | +15.79% | Beat | -12.0% | 2 | 0 up, 1 down | Oct 22, 2025 | $134.52M |
| Jun 30, 2025 | $0.19 | $0.18 | $0.17 - $0.18 | +5.56% | Beat | -13.6% | 2 | 0 up, 1 down | Jul 23, 2025 | $130.16M |
| Mar 31, 2025 | $0.14 | $0.15 | $0.14 - $0.17 | -6.67% | Miss | -26.3% | 4 | 0 up, 2 down | Apr 23, 2025 | $123.58M |
| Dec 31, 2024 | $0.22 | $0.22 | $0.19 - $0.23 | 0.00% | In line | +15.8% | 4 | 0 up, 0 down | Jan 29, 2025 | $129.24M |
| Sep 30, 2024 | $0.25 | $0.23 | $0.17 - $0.26 | +8.70% | Beat | +13.6% | 6 | 0 up, 1 down | Oct 23, 2024 | $134.40M |
| Jun 30, 2024 | $0.22 | $0.22 | $0.20 - $0.22 | 0.00% | In line | +4.8% | 7 | 1 up, 1 down | Jul 24, 2024 | $130.58M |
| Mar 31, 2024 | $0.19 | $0.15 | $0.15 - $0.17 | +26.67% | Beat | 0.0% | 7 | 0 up, 1 down | Apr 24, 2024 | $129.64M |
| Dec 31, 2023 | $0.19 | $0.19 | $0.18 - $0.21 | 0.00% | In line | -5.0% | 7 | 0 up, 0 down | Jan 31, 2024 | $128.21M |
| Sep 30, 2023 | $0.22 | $0.22 | $0.18 - $0.24 | 0.00% | In line | +22.2% | 8 | 0 up, 0 down | Nov 1, 2023 | $125.34M |
| Jun 30, 2023 | $0.21 | $0.21 | $0.19 - $0.22 | 0.00% | In line | +75.0% | 8 | 0 up, 1 down | Jul 26, 2023 | $127.88M |
| Mar 31, 2023 | $0.19 | $0.16 | $0.14 - $0.17 | +18.75% | Beat | +137.5% | 7 | 0 up, 1 down | Apr 26, 2023 | $128.36M |
| Dec 31, 2022 | $0.20 | $0.19 | $0.18 - $0.21 | +5.26% | Beat | 0.0% | 7 | 0 up, 0 down | Feb 1, 2023 | $127.57M |
| Sep 30, 2022 | $0.18 | $0.15 | $0.14 - $0.16 | +20.00% | Beat | 0.0% | 3 | 0 up, 0 down | Oct 26, 2022 | $125.97M |
| Jun 30, 2022 | $0.12 | $0.14 | $0.13 - $0.14 | -14.29% | Miss | -33.3% | 4 | 0 up, 0 down | Jul 27, 2022 | $120.90M |
| Mar 31, 2022 | $0.08 | $0.06 | $0.06 - $0.07 | +33.33% | Beat | -46.7% | 4 | 0 up, 0 down | Apr 27, 2022 | $115.30M |
| Dec 31, 2021 | $0.20 | $0.20 | N/A | 0.00% | In line | +11.1% | 4 | 0 up, 0 down | Feb 2, 2022 | $125.14M |
| Sep 30, 2021 | $0.18 | $0.19 | N/A | -5.26% | Miss | +12.5% | 4 | N/A | Oct 27, 2021 | $117.98M |
| Jun 30, 2021 | $0.18 | $0.19 | $0.18 - $0.21 | -5.26% | Miss | +28.6% | 10 | N/A | Jul 28, 2021 | $118.75M |
| Mar 31, 2021 | $0.15 | $0.13 | $0.10 - $0.18 | +15.38% | Beat | -51.6% | 12 | N/A | Apr 21, 2021 | $108.38M |
| Dec 31, 2020 | $0.18 | $0.16 | $0.10 - $0.17 | +12.50% | Beat | -52.6% | 12 | N/A | Jan 27, 2021 | $113.75M |
| Sep 30, 2020 | $0.16 | $0.15 | $0.09 - $0.19 | +6.67% | Beat | -68.0% | 15 | N/A | Oct 21, 2020 | $105.38M |
| Jun 30, 2020 | $0.14 | $0.12 | -$0.05 - $0.14 | +16.67% | Beat | -69.6% | 15 | N/A | Jul 22, 2020 | $115.74M |
| Mar 31, 2020 | $0.31 | $0.32 | $0.29 - $0.38 | -3.13% | Miss | -29.5% | 14 | N/A | Apr 22, 2020 | $152.40M |
| Dec 31, 2019 | $0.38 | $0.37 | $0.37 - $0.38 | +2.70% | Beat | -20.8% | 13 | N/A | Jan 29, 2020 | $156.78M |
| Sep 30, 2019 | $0.50 | $0.49 | $0.48 - $0.50 | +2.04% | Beat | -21.9% | 14 | N/A | Oct 23, 2019 | $173.20M |
| Jun 30, 2019 | $0.46 | $0.46 | $0.44 - $0.48 | 0.00% | In line | -22.0% | 14 | N/A | Jul 24, 2019 | $169.04M |
| Mar 31, 2019 | $0.44 | $0.43 | $0.41 - $0.44 | +2.33% | Beat | -22.8% | 13 | N/A | Apr 24, 2019 | $169.19M |
| Dec 31, 2018 | $0.48 | $0.49 | $0.44 - $0.53 | -2.04% | Miss | -17.2% | 15 | N/A | Jan 30, 2019 | $173.21M |
| Sep 30, 2018 | $0.64 | $0.63 | $0.60 - $0.64 | +1.59% | Beat | +33.3% | 14 | N/A | Oct 24, 2018 | $182.15M |
| Jun 30, 2018 | $0.59 | $0.59 | $0.58 - $0.59 | 0.00% | In line | +13.5% | 9 | N/A | Jul 25, 2018 | $175.47M |
| Mar 31, 2018 | $0.57 | $0.57 | $0.55 - $0.58 | 0.00% | In line | +35.7% | 12 | N/A | Apr 25, 2018 | $170.02M |
| Dec 31, 2017 | $0.58 | $0.58 | $0.56 - $0.60 | 0.00% | In line | +41.5% | 15 | N/A | Jan 31, 2018 | $171.85M |
| Sep 30, 2017 | $0.48 | $0.44 | $0.44 - $0.45 | +9.09% | Beat | +26.3% | 17 | N/A | Oct 23, 2017 | $166.25M |
| Jun 30, 2017 | $0.52 | $0.51 | $0.50 - $0.52 | +1.96% | Beat | +48.6% | 16 | N/A | Jul 24, 2017 | $163.90M |
| Mar 31, 2017 | $0.42 | $0.39 | N/A | +7.69% | Beat | +13.5% | N/A | N/A | Apr 19, 2017 | $157.81M |
| Dec 31, 2016 | $0.41 | $0.40 | N/A | +2.50% | Beat | -36.9% | N/A | N/A | Jan 25, 2017 | $149.54M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.76, down 13.6% from the year before. It was $1.51 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.76 | -13.6% |
| Dec 31, 2024 | $0.88 | +8.6% |
| Dec 31, 2023 | $0.81 | +39.7% |
| Dec 31, 2022 | $0.58 | -18.3% |
| Dec 31, 2021 | $0.71 | -10.1% |
| Dec 31, 2020 | $0.79 | -55.6% |
| Dec 31, 2019 | $1.78 | -21.9% |
| Dec 31, 2018 | $2.28 | +14.0% |
| Dec 31, 2017 | $2.00 | +32.5% |
| Dec 31, 2016 | $1.51 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,040 | 5 | |
| 2026Q2 | Jun 30, 2026 | 6,714 | 7 | |
| 2026Q1 | Mar 31, 2026 | 6,560 | 6 | |
| 2025Q4 | Dec 31, 2025 | 7,793 | 6 | |
| 2025Q3 | Sep 30, 2025 | 5,100 | 5 | |
| 2025Q2 | Jun 30, 2025 | 4,901 | 5 | |
| 2025Q1 | Mar 31, 2025 | 6,207 | 6 | |
| 2024Q4 | Dec 31, 2024 | 6,214 | 7 |
2026Q3 Earnings Call
Opening remarks
Lawrence Bruno Chairman and CEO Thanks, Cindy. Good morning in the Americas, good afternoon in Europe, Africa and the Middle East, and good evening in Asia Pacific. We'd like to welcome all of our shareholders, analysts and, most importantly, our employees to Core Laboratories Third Quarter 2026 Earnings Call. This morning, I'm joined by Chris Hill, Core's Chief Financial Officer, and Gwen Gresham, Core's Senior Vice President and Head of Investor Relations. The call will be divided into 6 segments. Gwen will start by making remarks regarding forward-looking statements. We'll then have some opening comments, including a high-level review of important factors in Core's Q3 performance. In addition, we'll review Core's strategies and the 3 financial tenets that Core Lab employs to build long-term shareholder value. Chris will then give a detailed financial overview and have additional comments regarding shareholder value. Following Chris, Gwen will provide some comments on the company's outlook and guidance. I'll then review Core's 2 operating segments, detailing our progress and discussing the continued successful introduction and deployment of Core Lab's technologies, as well as highlighting some of Core's operations, recent client interactions and major projects worldwide. Then we'll open the phones for a Q&A session. I'll now turn the call over to Gwen for remarks on forward-looking statements.
Gwendolyn Schreffler Senior Vice President and Head of Investor Relations Before we start the conference this morning, I'll mention that some of the statements that we make during this call may include projections, estimates and other forward-looking information. This would include any discussion of the company's business outlook. These types of forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from our forward-looking statements. These risks and uncertainties are discussed in our most recent annual report on Form 10-K, as well as other reports and registration statements filed by us with the SEC. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Our comments also include non-GAAP financial measures. Reconciliation to the most directly comparable GAAP financial measures is included in the press release announcing our third quarter results. Those non-GAAP measures can also be found on our website. With that said, I'll pass the discussion back to Larry.
Lawrence Bruno Chairman and CEO Thanks, Gwen. Moving now to some high-level comments about our third quarter 2026 results. Compared to the second quarter, operational performance improved nicely with higher revenue, operating income, operating margins and earnings per share. Core continued to execute its strategic plan of technology investments targeted to both solve client problems and capitalize on Core's technical and geographic opportunities.
Frequently Asked Questions About CLB
Did CLB beat earnings estimates last quarter?
No. Core Laboratories NV reported EPS of $0.16 for the quarter ended Sep 30, 2026, below the $0.17 estimate by 5.88%.
What EPS do analysts expect from CLB next quarter?
The consensus EPS estimate for Core Laboratories NV for the quarter ending Dec 31, 2026 is $0.17 from 4 analysts, with estimates from $0.15 to $0.20.
How often does CLB beat earnings estimates?
Core Laboratories NV beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +1.42%.
CLB pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors